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Abstract
Alzheimer’s disease (AD) is the most common form of dementia and is characterized by
progressive neuronal loss and cognitive decline. Currently, no therapeutic treatments are
available and our understanding of the disease progression is still unclear. Amyloid beta
oligomers (AβO) are potent neurotoxic proteins and may be a potential initiator of the
progression of AD. The purpose of this project was to identify the spatial and temporal
consequences of injecting AβO into the rat brain by evaluating pathological and
behavioural outcomes. We hypothesized that injecting AβO into the rat brain will result in
microglial response as well as behavioural and cognitive deficits. Synthetic AβO were used
for this study and characterized by western blot. AβO were injected
intracerebroventricularly (ICV) into the rat brain and a timeline was established at 1, 3, 7
and 21-days post-surgery. Immunohistochemistry was used to stain the sections for AβO
deposition, microglial response, and cholinergic neurons. Behavioural analyses included
the Morris Water Maze task for spatial learning and memory and open field for exploratory
and anxiety-like behaviours. Our data showed that ICV injections of AβO resulted in AβO
deposition in the walls of ventricles and a subtle and transient deficit in spatial learning and
memory as well as anxiety-like behaviours. No differences in microglial response within
the hippocampus, basal forebrain, corpus callosum, internal capsule, and fimbriae of
hippocampus were observed. In addition, no significant differences were observed with
cholinergic neuron numbers in the basal forebrain (medial septum, vertical and horizontal
diagonal bands of Broca). Overall, our results indicate that injection of AβO into the rat
brain may be an alternative, non-transgenic strategy to investigate the effects of AβO in an
in vivo model.
Key Words: Alzheimer’s Disease, Amyloid Beta Oligomers, Non-transgenic Rat Model,
Western Blot, Immunohistochemistry, Behavioural Analysis, Morris Water Maze, Open
Field, Microglial Response, Cholinergic Neurons
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Part 1: Introduction

1

1.1

Alzheimer’s Disease: Socioeconomic Impact and Relevance
Alzheimer’s disease (AD) is the most common form of dementia1. It is the sixth leading

cause of death and fifth for those aged 65 and older2. In 2010, the estimated total for dementiarelated costs was upwards of $604 billion worldwide3 and the economic burden is expected to
increase. Age is one of the greatest risk factors for AD4,5 and Canada has a rapidly aging
population. By 2041, Canadians aged 65 and older is expected to reach approximately 25% of our
total population2. Therefore, researchers need to develop therapeutic treatments for the disease that
can either cure or delay its onset.
1.2

Alzheimer’s Disease: Definition and Clinical Symptoms
Alois Alzheimer, defined AD in 1907 with two pathological hallmarks: amyloid plaques

and neurofibrillary tangles6. AD is characterized by a progressive loss of neurons and cognitive
decline. Symptoms include memory loss, anxiety, mood/personality changes, decreased judgment,
disorientation, and impaired communication7. Physicians can clinically diagnose “probable AD”
by following a set of guidelines and comprehensive testing, but a “definitive AD diagnosis” can
only be done by post-mortem histopathological analysis8.
1.3

Pathophysiology of AD
AD is diagnosed in post-mortem human brains by the presence of amyloid plaques and

neurofibrillary tangles (NFTs). Other pathological correlates of AD include: elevated
inflammatory responses and extensive neurodegeneration within the brain. The following section
aims to summarize the findings of each characteristic in human studies.
Amyloid plaques have dominated the field of AD research over the past two decades. They
are primarily composed of aggregated extracellular deposits of amyloid beta (Aβ) fibrils. Although
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variable between individuals with AD, amyloid plaques can be found throughout the brain
although appear more frequently in certain regions9,10. Plaques can be categorized as diffuse or
dense-core, although only the latter is associated with neurotoxicity10. Amyloid plaques are
considered as the primary initiator of AD progression in the amyloid cascade hypothesis11, which
will be discussed in later sections.
NFTs are intracellular tau proteins that are abnormally phosphorylated and become
misfolded. Unlike amyloid plaques, NFTs appear in a more distinctive pattern within the AD brain.
They begin forming in the entorhinal cortex and continue to form in the hippocampus, amygdala,
thalamus, and claustrum10. Clinically, AD progression can be characterized based on the degree of
NFT pathology according to Braak Staging9. NFTs are usually a late occurring event in AD
progression, but recent studies have also given more emphasis to NFTs as potential therapeutic
targets12–14. This is based on evidence supporting the positive correlation between NFTs with the
severity of clinical symptoms and therefore may show more potential as a target for therapeutic
intervention14.
Inflammatory responses play an important role in neuroprotection but are also a key
contributor in the pathogenesis of AD. Inflammation is a broad term that includes many interacting
factors, such as the complement system, various cytokines and chemokines such as interleukin
(IL) -1, IL-6, tumor necrosis factor alpha (TNF-α), transforming growth factor beta (TGF-β), and
cell-mediated responses like microglia and astrocytes, which all contribute to AD pathology15. AD
is associated with an overactive and prolonged inflammatory response that occurs early in the
pathogenesis of AD. Studies examining post-mortem human AD brain tissue revealed that
excessive microglial activity is toxic to neighboring neurons16,17 and chronic inflammation can be
detrimental to the brain altering the structural integrity of neurons leading to neurodegeneration18.
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It has also been demonstrated that inflammation within the AD brain starts within the limbic
system, including entorhinal cortex and hippocampus18. The importance of inflammatory
responses in the progression of AD has led to extensive research on the potential therapeutic
potential of anti-inflammatory agents19.
Late stage AD is characterized by extensive neurodegeneration leading to atrophy. Atrophy
can occur within the cerebral cortex and hippocampus, and the resulting tissue loss leads to
increased volume within the ventricles especially at the temporal horn of the lateral ventricles20.
Neurodegeneration in AD is associated with apoptosis21,22. Post-mortem analysis of the AD brain
revealed increased apoptotic neurons compared to non-AD patients23–25, the majority of which
occurred within the entorhinal cortex and hippocampus23.
1.4

Amyloid Beta (Aβ) Protein
Aβ occurs naturally in humans and can be found in the cerebral spinal fluid (CSF) and

blood. However, AD is associated with the abnormal accumulation of misfolded Aβ proteins that
cause neurotoxic effects in the brain26–29. Aβ is derived from the sequential cleavage of the
transmembrane protein amyloid precursor protein (APP)30–33. This cleavage is caused by the
activity of two enzymes, β- and γ- secretase, cleaving the N- and C- terminal respectively from
APP34,35. The γ- secretase can cleave at multiple sites, giving rise to various Aβ peptide lengths
ranging from 39-43 amino acids36,37. Of the various lengths of Aβ protein, Aβ40 is the most
prevalent and Aβ42 is considered the most neurotoxic38.
After Aβ is cleaved from APP, the protein can fold and form different conformations of
Aβ peptides, including monomers, oligomers, protofibrils, and fibrils. The pathway in which
these structures form is still controversial. Mainly, oligomers can be considered an end-product
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or an intermediate structure of a pathway leading to Aβ protofibrils and fibrils39–41. In addition,
the different Aβ protein conformations are believed to be dynamic. This means that the
structures are interchangeable, i.e. Aβ fibrils can change into Aβ oligomers and vice versa42. AD
is a complex disease, especially when considering the main protein of interest has varying amino
acid lengths, different types of species, and a dynamic nature.
Aβ protein plays a major role in the pathogenesis of AD and is a primary constituent of
amyloid plaques, a pathological hallmark of the disease. Beyond the relationship between Aβ and
amyloid plaques, several reasons exist that lead researchers to emphasize the significance of Aβ
in pathogenesis of AD. Most of the evidence that support this claim relates to the genetic mutations
that occur in early-onset AD patients. These mutations often occur in genes that relate to the
synthesis of Aβ protein that ultimately increases Aβ production43.
Studies have attempted to describe the progression of Aβ deposition in AD brains. Thal et.
al. 200244, described the regional progression of Aβ deposition in five phases. These phases begin
with Aβ deposition in regions of the neocortex in phase one, allocortical brain regions in phase
two, diencephalic nuclei, striatum, and basal forebrain in phase three, brainstem in phase four, and
finally cerebellum in phase five. Other methods have also been used to describe Aβ deposition
with similar results in human AD brains such as using positron emission tomography to detect the
Pittsburg compound B that binds to fibrillar Aβ protein45,46.
1.5

Amyloid Cascade Hypothesis
The most prominent hypothesis to explain the pathogenesis of AD is the “amyloid cascade

hypothesis”11 (Figure 1.). This hypothesis postulates that Aβ protein is the primary constituent of
the amyloid plaques found within the AD brain47. It further postulates that the extracellular
5

deposition of Aβ peptides in the brain form fibrils that aggregate into extracellular insoluble
plaques that, in turn, initiate a cascade of downstream events, including the abnormal
phosphorylation of tau protein, all of which lead to cognitive decline48.
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Figure 1

Aβ Deposition

Amyloid Plaques

Inflammatory Response

Progressive Neuronal Injury

Neurofibrillary Tangles

Neuronal Death

Cognitive Decline/ Dementia

Figure 1. Schematic diagram depicting the amyloid cascade hypothesis. The hypothesis begins
with Aβ deposits aggregating into amyloid plaques, which cause a cascade of events that lead to
cognitive decline and dementia. (Adapted from Selkoe, 2001)
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Although there is a litany of evidence in literature to support this hypothesis49–51, there are
significant issues that exist that may not fully support it. There is still a disconnect between
cognitive decline in AD patients and Aβ deposition. First, there is a poor correlation between
density and location of the plaques and the severity of cognitive decline52–55. In these studies,
patients have been shown to possess significant levels of plaque development at the earliest
diagnosed stages of AD. Second, post-mortem analysis of human brains, from patients not
diagnosed with AD, can still possess amyloid plaques. In a study by Crystal et. al. 198856, amyloid
plaques were found in the cortex in six of the nine non-demented elderly brains. Studies have even
included such patients as high pathology controls, where non-demented patients demonstrated
extensive plaque development57. Third, amyloid plaques may be deposited in response to brain
injury in general. Patients that survived a head injury have been shown to develop pathology
similar to AD patients, including increased expression of APP, overproduction of Aβ protein, and
plaque deposition58. Fourth, AD animal models that overexpress human mutated APP,
overproduce Aβ protein, and develop amyloid plaques may not show any cognitive deficits. For
example, Tg2576 mice do not develop cognitive deficits until 5 months after amyloid plaques are
deposited59. Conversely, transgenic rat models of AD overexpressing human mutated APP can
develop cognitive and behavioural changes such as deficits in spatial learning and memory and
altered exploratory behaviour in the absence of plaque deposition60,61. These evidence suggest that
the amyloid cascade hypothesis may not fully describe the pathogenesis of AD, and perhaps other
factors may be at play.
1.6

Amyloid Beta (Aβ) Oligomers
Growing evidence in the field is supporting amyloid beta oligomers (AβO) as a potential

initiator in the pathogenesis of AD. In a study, it was found that purified human serum clusterin
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blocked the aggregation of Aβ fibrils resulting in deposition of ‘soluble’ Aβ species. These soluble
Aβ proteins were found to be more neurotoxic than aggregated Aβ fibrils using the cell viability
assay, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay62. Subsequent
studies were able to identify that these soluble Aβ proteins were AβO63. Due to the structure of
AβO, these proteins were previously undetected with the methods used to detect Aβ plaques, such
as Thioflavin T64.
AβO are a class of Aβ peptides that have aggregated into oligomeric structures that can
range from dimers to 24mers. Human studies have shown that AβO correlate well with severity of
the disease, including synaptic changes and neurodegeneration54,57, which was not shown
previously with amyloid plaques. Unlike amyloid plaques that are localized in one area, soluble
AβO can theoretically diffuse to different regions of the brain, which can help explain the extensive
neurodegeneration observed in late-AD pathology62. In one study that compared frontal cortex
brain extracts from five AD patients compared to five age-matched controls, average AβO detected
in AD brains were approximately 12-fold higher than the control group52. In rats, Human-brain
extracted AβO have been shown to impair synaptic plasticity and learning behaviours in the
passive avoidance conditioning test65. Other studies have also suggested that AβO can be detected
in human cerebral spinal fluid, and may serve as an early diagnostic tool to predict AD66. Together,
these results indicate that AβO may play an important role in AD and has led to a modified amyloid
cascade hypothesis that focuses on the soluble AβO as the primary initiator of AD pathogenesis.
1.7

Preparations of Aβ Oligomers in Research
AβO can be prepared in a variety of ways. Although there are several different methods to

produce AβO, the proteins from each protocol are still structurally similar52,67. In this study, AβO
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were derived synthetically, but AβO can also be derived “naturally” from human AD brains, brains
from AD animal models, and cell cultures that overexpress human APP68–70.
One of the first and most established protocols for synthetic AβO was described by
Lambert et. al. in 199863. This protocol formed the basis for AβO preparation in the present study.
AβO created from this protocol has been structurally characterized by various techniques such as
western blot, atomic force microscopy, size exclusion chromatography, and mass spectrometry
and range from 3-24mer63,71. When treated on rat hippocampal slices, this AβO preparation has
been found to impair long-term potentiation at concentrations as low as 500 nM63. The main
advantage for using synthetic AβO is its accessibility where studies can use and produce AβO in
the laboratory.
1.8

Animal Models of AD
Animal models have played an important role in our understanding of the pathogenesis of

AD and continue to provide the basis in developing potential therapeutic agents. To date however,
most treatments that have been developed and proven effective in reducing AD symptoms in
animal models have not translated to successful human clinical trials72. This may be due to
incomplete animal models that do not fully mimic the disease. An ideal animal model should
recapitulate all aspects of AD pathology seen in humans72,73, which may lead to more effective
therapeutic testing and, therefore, successful human clinical trials.
Mice are a popular animal model for AD. These mice models are often transgenic and are
modelled to overexpress mutated human APP74. When studying these mice models, most form
amyloid plaques in an age-dependent manner, i.e. more amyloid plaques develop as the mice grow
older, display deficits in spatial learning and memory with MWM, but won’t display the same
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magnitude of neurodegeneration as seen in human AD patients74. For example, Tg2576 mice,
overexpresses mutated human APP, have demonstrated elevated levels of Aβ at 6 months of age,
form amyloid plaques in various brain regions by 9-10 months of age that coincide with deficits
observed in spatial learning and memory70. In addition, these mice displayed age-dependent
increases in Aβ within the brain and decrease in the CSF as the mice age, similar to the pattern
observed in humans75. However, neurodegeneration doesn’t occur up to 23 months of age70. Mice
models have provided insight to understanding the relationship between Aβ and amyloid plaques,
however, the pathological analysis is often more reflective of early-stage AD72.
Rats are becoming more popular as an AD model as they are relatively cheap, easy to
maintain, and can perform a variety of complex behavioural tasks, which is useful for testing
cognitive or behavioural deficits76. Rats have a natural resistance to AD (i.e. it doesn’t occur
naturally) and are difficult to manipulate genetically77. Recent technological advancements,
however, has allowed researchers to manipulate the rat genome more easily, thus making
transgenic rat models more feasible.
1.9

Transgenic Rat Models
Several transgenic rat models have been developed that overproduce human Aβ protein.

Although each transgenic rat model expresses a mutated form of human APP, they can differ by
several factors. These factors include differences in APP isoform, type of mutation that the gene
carries, type of promoter used to control genetic expression, and the rat strain used to develop the
model76. An important factor is the mutation that they carry as it directly affects the expression of
Aβ. Common mutations that transgenic models carry include the Swedish mutation, defined as
K670N/M671L (letters represent single amino acid codes) and Indiana mutation, defined as
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V717F42 (Figure 2.). These mutations are positioned at the N and C-terminals of Aβ on APP,
where they regulate and increase the production of Aβ4242. This section aims to summarize some
of the important findings from transgenic rat models.
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Figure 2

Figure 2. Schematic diagram indicating the Swedish and Indiana mutations on the APP
protein. Letters represent the single letter amino acid codes. Swedish mutation is defined as
K670N/M671L and Indiana mutation is defined as V717F. Diagram was adapted from Selkoe
(2001).
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Transgenic rat models have continued to provide support for Aβ as an important initiator
in the pathogenesis of AD. For example, UKUR25 rat model carries three mutations: Swedish,
Indiana and Finn78. Finn mutation results in the expression of a mutated human form of presenilin1, which is an important enzyme in the regulation of Aβ protein by manipulating the effects of γsecretases to overproduce Aβ42 specifically79,80. Each of these mutations act to increase the
production of Aβ42, the most toxic form of Aβ38. Studies using this rat model have shown increases
in intracellular Aβ accumulation in hippocampal and cortical neurons as early as 6 months of age
without ever developing amyloid plaques up to 24 months78,81,82. The APP21 strain is another
transgenic rat carrying both human Swedish and Indiana mutations83. These rats showed
significant increases in APP mRNA levels in the brain as well as increased Aβ found in serum83.
Aβ deposition has not been observed in APP21 rat model for up to 30 months, however, it has
been shown that it can be exogenously seeded to develop plaques after nine months if injected
with cortical brain extracts derived from human AD brain84. Although amyloid plaques do not
spontaneously develop in the UKUR25 or APP21 models, this could potentially hint to other forms
of Aβ, such as AβO, being the principal driver leading to the cognitive deficits. Results from the
different models continue to support the significant role of Aβ in the pathogenesis of AD.
Transgenic rat models have correlated certain pathological aspects of AD with behavioural
and cognitive deficits. Unlike transgenic AD mice, rats can undergo more complex behavioural
and cognitive testing. Studies using the transgenic rat model UKUR25 have suggested that
intracellular Aβ accumulation can correlate with cognitive deficits in spatial learning with the
Morris water maze (MWM)81. Tg6590, a transgenic rat model carrying the Swedish human APP
mutation, was reported to show increased levels of Aβ in the brain parenchyma and
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cerebrovascular blood vessels85, which correlated with deficits in spatial learning with the MWM
and exploratory behaviour with open field (OF)60. Another transgenic rat model, McGill-R-Thy1APP, overexpressing human APP and carrying Swedish and Indiana mutations displayed increases
in intracellular Aβ deposition throughout cortical and hippocampal neurons as early as one-week
post-natal and extracellular Aβ plaques by six months of age86. Spatial learning in this transgenic
rat model was detected as early as three months of age using the MWM and continued to worsen
to 13 months86. The study concluded that spatial learning deficits correlated with AβO deposition
and not plaques. Together, these models suggest that increased AβO deposition may correlate
better with behavioural and cognitive deficits in rats than amyloid plaques.
Although transgenic rat models have provided more insight to the understanding of the
disease, these models are more representative of familial forms of AD, which only account for 510% of all AD cases34. Perhaps a more representative model for the more prevalent sporadic form
of AD would be to develop a non-transgenic rat model87. Additionally, most transgenic rodent
models overproducing Aβ have yet to recapitulate the same degree of neurodegeneration and
synapse loss seen in humans and perhaps a different approach to developing an AD model may be
necessary57,72.
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Table 1. Overview of transgenic rat models used in the field. This however, does not
represent a comprehensive list of all AD rat models.
Rat Model

Approach

Pathology

Behaviour

UKUR25

Transgenic

Accumulation of
intracellular Aβ in cortex
and hippocampus at 6
months of age.

Impaired spatial
learning with MWM
in correlation with
accumulation of
intracellular Aβ.

No plaques were
developed as late as 24
months of age.
Tg6590

APP21

Transgenic

Transgenic

Increased Aβ levels in
brain parenchyma and
cerebrovascular blood
vessels.

Impaired spatial
learning at 9 months
of age with MWM.

Aβ plaques developed at
9 months of age if
exogenously seeded
with human cortical
brain extracts from AD
patients.

n/a

OF analysis showed
reduced exploratory
behaviour.

No Aβ deposits observed
as late as 30 months of
age.
McGill-R-Thy1-APP

Transgenic

Accumulation of
intracellular Aβ in cortex
and hippocampus as
early as one-week post
natal.
Extracellular Aβ plaque
by 6 months of age.

16

Impaired spatial
learning with MWM
at 6 months of age.
Deficits increased
until 13 months of
age.

1.10

Non-Transgenic Rat Models of AD
Several approaches have been used to produce non-transgenic rat models of AD and most

involved chemical injections. Non-transgenic models varied in many ways, from the chemical
being injected, to the number and location of the injections. In the past, many non-transgenic
models targeted cholinergic neurons by injecting chemicals such as choline mustard aziridinium
ion88–90. But the shift towards the amyloid cascade hypothesis in the 1990s saw the development
of non-transgenic models with Aβ peptide injections91. Different peptide fragments such as Aβ2535,

Aβ1-40, and full length Aβ1-42 have been used92–95. Infusion approaches can vary from a single

acute injection, multiple single injections, or chronic infusions using osmotic pumps91,96. Location
of the injection also differed from amygdala97, hippocampus98, and lateral ventricles99,100.
However, few studies have looked into the effects of injecting amyloid beta oligomers in a nontransgenic rat model.
Past studies have demonstrated that injecting Aβ into brains of non-transgenic rats is a
viable model for AD as it produced AD-like pathology and cognitive deficits. Following Aβ42
injection into the hippocampus, rats showed deficits in social recognition memory with social
recognition test93. Another group that also injected Aβ42 in the hippocampus of rats showed
elevated astrocyte response and the rats performed worse in the alternating-lever cyclic-ratio task,
indicating deficits in tracking changing parameters, spatial memory and preservations. A study
that performed multiple injections of Aβ40 in the hippocampus of the rat showed deficits in short
term working memory using the delayed conditional discrimination task that was not seen after a
single acute injection92. Aβ25-35 peptide injections in the lateral ventricles have also shown altered
behavioural performances with the radial arm maze task and neuronal loss in the hippocampal
CA1 region95. Our lab have previously done a similar study injecting Aβ25-35 into the lateral
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ventricles and found deficits in long term spatial memory in MWM task, cholinergic loss and
elevated inflammatory response in the basal forebrain94,101–104. Together, these results represent
the feasibility of developing a non-transgenic rat model by injecting Aβ peptides.
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1.11

In vitro effects of AβO
Many studies have focused on understanding the neurotoxic effects of AβO in vitro. The

potent neurotoxicity established in these studies combined with findings that support elevated
levels of AβO in AD-brains have highlighted the potential role of AβO in the pathogenesis of AD.
AβO have been proposed to bind to many receptors, such as cellular prion protein (PrPc) receptors,
metabotropic glutamate receptors (mGluR), N-methyl-D-aspartate (NMDA) receptor, α-amino-3hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor, etc., yet the exact mechanisms
underlying the disease pathogenesis are still unclear105. AβO can either bind specifically to certain
receptors or promiscuously to multiple receptors that ultimately lead to neurotoxic effects,
cognitive decline, and dementia105.
AβO have been shown in in vitro studies to target synapses and cause functional deficits
prior to neuronal death. AβO are found to co-localize preferentially with post-synaptic density
(PSD)-95, a marker for post-synaptic dendrites, in cell cultures of hippocampal neurons106. The
study also found that AβO co-localize with and upregulate activity-related cytoskeletal-associated
(Arc) protein, which plays a critical role in long term potentiation (LTP)106. AβO association with
Arc upregulation in hippocampal neurons suggest that LTP may be disrupted, thus also affecting
learning and memory. In another study, AβO was shown to selectively bind to synapses of rat
hippocampal and cortical but not cerebellar neurons when incubated in cell cultures52. Using the
MTT cell viability assay, the study also found that AβO are selectively more toxic to cortical but
not cerebellar neurons52. Hippocampal slices from transgenic mouse models overexpressing
human mutated APP were found to have altered synaptic transmission and LTP. Further studies
that treated AβO directly on the cultured mouse hippocampal slices have been shown to
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immediately disrupt LTP63,107,108. These results confirm that AβO are potent neurotoxic proteins
that can target synapses and disrupt their functional activity in vitro.
AβO are associated with activating inflammatory cells like microglia. AβO can bind to
receptors on microglia which can, in turn, release inflammatory cytokines and chemokines to
promote neuroinflammation109,110. In vitro studies have shown that AβO can bind to microglial
receptors such as toll-like receptor (TLR)-4 resulting in a release of inflammatory products such
as interleukin (IL)-6, tumor-necrosis factor alpha (TNFα), and nitric oxide that is neurotoxic to
mouse hippocampal neurons109–111. Microglia can also clear AβO through phagocytosis and
receptor-mediated endocytosis in vitro. Studies have suggested the role of microglial receptors
such as cluster of differentiation (CD)-36 with phagocytosing and uptake of AβO in rat microglial
cultures112. The role of microglia and its response to AβO, however, is still unclear. In vitro studies
have had contradictory results regarding the role of microglia in AβO clearance. For example, a
study concluded that AβO in the presence of microglia exacerbated the neurotoxic effects of AβO
in cell cultures of mouse cortical neurons113. Yet another study suggested that activated microglia
can attenuate the neurotoxic effects of AβO in mouse cortical neuron cell cultures114. Although
contradictory, these results help reinforce the complex and intricate role of microglia in the
pathogenesis of AD.
1.12

In vivo effects of AβO
Support for AβO as potent neurotoxic proteins are strong in in vitro studies, but these

results could be neglecting many factors that occur in a physiological environment. In vivo studies
play an important role in the understanding of AβO and its biological relevance and can also
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provide insight into how AβO-induced functional deficits will affect the animal’s performance in
behavioural tasks.
AβO have been detected in several transgenic AD animal models. It has been reported that
AβO induce the cognitive impairments observed in several transgenic mice models that contain
mutated human APP gene and overproduce Aβ protein. For example, studies using Tg2576 found
that AβO in mice brains contributed to the deficits in spatial learning and memory as detected by
the MWM task59,115. In addition, when anti-AβO antibodies were administered to Tg2576 mice,
cognitive deficits were attenuated116. The presence of AβO in AD animal models and its
contribution to cognitive impairments, help solidify the importance of AβO in AD pathogenesis.
Exposing AβO to animal brains has also been shown to induce functional and cognitive
deficits. Using the Tg2576 mice model as described above, AβO were extracted from older
cognitively-impaired

mice

brains.

These

extracted-AβO

were

then

injected

intracerebroventricularly (ICV) into young non-cognitively impaired mice. After being exposed to
the extracted-AβO, the mice demonstrated impaired spatial learning and memory in the MWM
task115. Other studies that observed the effects of AβO on synaptic activity, found that AβO were
synaptotoxic immediately after being injected in vivo into rodent brains. LTP was completely
blocked at 3 h post-high frequency stimulation after ICV injection of cell-secreted AβO in rat
brains69,117. This group also showed that LTP inhibition was abrogated following treatment with
AβO-specific antibodies69,117. Similar results of LTP inhibition were found using either cellderived AβO or human brain-derived AβO118–120. These results suggest that AβO can impair LTP
and also induce cognitive deficits in vivo.
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1.13

Rationale
To date there are no effective therapeutic treatments for AD, mainly due to our incomplete

understanding of its pathogenesis. Ideally, therapeutic treatments should focus on the earliest
pathological changes in order to have the best chances to develop a treatment that can either cure
or delay its onset. This is because the disease at its later stages may already be irreversible. One
hypothesis in the field considers AβO, a potent neurotoxic protein, as a primary initiator to the
pathogenesis of AD. Few have looked into the effects of AβO in vivo and even fewer for its effects
in non-transgenic rats121,122. The effects of AβO in a non-transgenic rat model may be critical to
our understanding of sporadic AD, the more prevalent form of the diease. Therefore, the purpose
of the study is to investigate the effects of injecting synthetic AβO into a rat and characterizing its
pathological and behavioural consequences.
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1.14

Hypothesis and Aims

Hypothesis – Exposure of AβO will result in an activated microglia response as well as cognitive
and behavioural deficits.
Aim 1 – Compare the pathological effects of AβO when injected within the lateral ventricles of
the rat at 1, 3, 7, and 21-days post-surgery.
Aim 2 – Evaluate the effects of spatial learning and memory, and exploratory and anxiety-like
behavior after AβO were injected within the lateral ventricles of the rat.
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Part 2: Methodology

24

2.1

Synthetic AβO Preparation
Aβ1-42 (Bachem, Bubendorf, Switzerland) peptide was purchased and stored at -20°C until

use. Ice-cold 1,1,1,3,3,3-hexafluro-2-propanol (HFIP, Sigma Aldrich, St. Louis, MO) was added
to the peptide to dissolve and monomerize it and made to a final concentration of 1 mM. The
resulting solution was vortexed and aliquoted into microcentrifuge tubes with 10 µL in each
sample. These tubes were air-dried on ice for 10-15 min and then lyophilized for 1 h to ensure that
the HFIP had completely evaporated. The resulting peptide was stored at -80°C until use. Tubes
were only taken out prior to use and 10 µL of anhydrous dimethyl sulfoxide (DMSO, BioShop,
Burlington, ON) was added to re-dissolve the peptide pellet. The solution was pipetted up and
down several times to ensure that the pellet was dissolved completely and then sonicated for 10
min at 37°C. Ten mM phosphate buffered saline (PBS, pH 7.4) was added to make a final
concentration of 150 µM. Immediately after the PBS was added, the peptide solution was either
used as Aβ monomers, or incubated at 4°C for 24 h and used as AβO.
2.2

Western Blot analysis of AβO
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was performed

using the BioRad Mini-Protean Tetra Handcast Systems (Bio-Rad Laboratories Inc., Hercules,
CA). Aβ monomer and oligomer samples were loaded in a 4% stacking gel at 60 V for 15 min
and separated in a 16.5% resolving gel at 100-120 V for 75-90 min. Gels were run in tricine
buffer and subsequently wet-transferred on to a nitrocellulose membrane overnight at a constant
current of 15 mA at 4°C. Following the transfer, the nitrocellulose membrane was rinsed 3 x
with 15 mM tris-buffered saline with tween 20 (TBST, pH 7.5). The membrane was then blocked
with 5% non-fat milk for 1 h on a shaker at room temperature (RT) and then incubated in
primary antibody diluted in 5% non-fat milk on a shaker overnight at 4°C and then 30 min at RT
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the next morning. Primary antibodies include: Aβ4G8 (1:500, Covance, Princeton, NJ) which
detects Aβ peptide at the 17-24 AA sequence, and A11 (1:1000, Millipore, Billerica, MA) which
detects oligomer-specific amyloid species123. Following primary antibody incubation, the
membrane was rinsed with TBST 3 x and then washed in TBST for 3 x 10 min washes on a
shaker. Finally, the membrane was incubated in fluorescent secondary antibody diluted in 5%
non-fat milk for 1 h at RT on a shaker, while kept in the dark. Fluorescent secondary antibodies
included: anti-mouse IgG and anti-rabbit IgG (1:10, 000, DyLight 680 nm, Thermo Scientific,
Rockford, IL). Membrane was again rinsed with TBST 3 x and then submerged in TBST for 3 x
10 min washes on a shaker. Images of the membrane were taken with an Odyssey CLx Imager
and software program (LI-COR Biosciences, Lincoln, NE).
2.3

Animals and Surgical Procedures
All procedures followed the guidelines of Canadian Council on Animal Care and Western

University Animal Use Subcommittee. Six-month old male Wistar rats (Charles River Canada)
were housed individually and randomly assigned to an experimental or control group. Food and
water were provided ad libitum. Rats were allowed to habituate in their new environment for one
week prior to surgery.
Rats were anesthetized with 3% isoflurane (Baxter Corporation, Mississauga, ON),
weighed, and shaved at the top of their heads where the incision would be made. With a stereotaxic
apparatus, their heads were immobilized using ear bars and a mouth-piece and rats were kept under
2% isoflurane throughout the surgery. Body temperature was controlled with a heating pad set at
37°C. The shaved area was then sterilized with soap, ethanol and iodine. Bregma was located and
arbitrarily set with stereotaxic units AP: 0 mm, ML: 0 mm, DV: 0 mm. Intracerebroventricular
(ICV) injections were AP: -0.8 mm, ML: ±1.4 mm, DV: -4.0 mm. Using Hamilton syringes
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(Hamilton, Reno, NV), either AβO or PBS were injected. For bilateral ICV injections, 17 µl of the
solution was injected in each ventricle (34 µl total volume and ~23 µg of AβO). Rate of injection
was approximately 1 µl/min. Rats were then sutured and administered with 0.1 mL/100 g
buprenorphine (0.3 mg/mL, Reckitt Benckiser Healthcare, Oakville, ON) and 0.03 mL of Baytril
(Bayer, Toronto, ON) intramuscularly. After surgery, rats were placed on their backs and
monitored in a cage under a heat lamp until they recover from the anesthesia.

27

Table 2. Summary of animal groups treated with PBS or AβO and their respective n-values.
Days refer to number of days post-surgery.
1 Day

3 Day

7 Day

21 Day

PBS

n=5

n=5

n=5

n=8

AβO

n=5

n=5

n=5

n=8
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Figure 3. Surgical timelines and injection sites. (A) Amyloid beta oligomers (AβO) were
incubated at 4°C for 24 hours prior to surgeries. Rats were fixed onto a stereotaxic frame and
injected with either AβO or phosphate-buffered saline (PBS) as control. Rats were sacrificed 1, 3,
7, (n=5) and 21-days (n=8) post-surgery. (B) 150µM AβO concentration were injected bilateral
intracerebroventricularly (~23 µg, blue arrows). Equivalent volumes of 0.01 M PBS was injected
for control. (C) Stereotaxic units (ML, AP, DV) used for ICV injections: -0.8 mm, ±1.4 mm, -4.0
mm. Blue arrows/dots represent the areas where ICV injections were inserted respectively.
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2.4

Brain Extraction and Tissue Sectioning
Rats were euthanized 1, 3, 7, or 21 days post-surgery with an intraperitoneal injection

(~0.5-0.8 mL) of 240 mg/mL pentobarbital sodium or Euthanyl (Bimeda-MTC, Cambridge, ON).
Animals were then perfused trans-aortically with 0.01 M PBS for 3 min and 4% paraformaldehyde
(PFA, diluted in 0.01M PBS) for 7 min respectively. Brains were removed and immediately placed
in 4% PFA for 24 h at 4°C. Brains were then transferred to 30% sucrose for 72 h. Brains were
sliced with a CryoStar Nx50 (Thermo Scientific, Waltham, MA) in 35µm coronal sections and
stored in cryoprotectant solution (30% sucrose, phosphate buffer pH= 7.2, and ethylene glycol) at
-20°C until ready for use.
2.5

Immunohistochemistry

For primary antibodies: Aβ4G8, IBA-1, Ox-6, and ChAT.
To completely remove the cryoprotectant, sections were washed with 0.01 M PBS (this
concentration was used for all immunohistochemistry procedures outlined below) for 6 x 10 min
washes. Next, a 10 min wash with 1% hydrogen peroxide (Fisher Chemicals, Fair Lawn, NJ) was
performed to block endogenous peroxidase activity. Tissue was then washed 3 x 5 min with PBS
and then incubated for 1 h r in blocking buffer, which consisted of secondary antibody specifies
raised serum (1:500) diluted in PBS with 0.2% triton-X100 surfactant (PBST). Sections were
subsequently incubated in primary antibody diluted in blocking buffer for 1 h at RT and then
overnight at 4°C. Primary antibodies include: Aβ4G8 (1:500, Covance, Princeton, NJ which
detects Aβ peptide at the 17-24 AA sequence, OX-6 (1:1000, Pharmingen, San Jose, CA) which
detects activated microglia by binding to the major histocompatibility complex (MHC) class II,
IBA-1 (1:1000, Wako, Richmond, VA) which detects all microglia and is directed against the
ionized calcium binding adapter molecule, and choline acetyltransferase (ChAT, 1:500, Abcam,
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Cambridge, MA) which detects cholinergic neurons via the anti-choline acetyltransferase enzyme.
(Table 2). Sections were then subjected to 3 x 5 min washes in PBS and then incubated in
secondary anti-IgG antibody diluted in blocking buffer for 1 h. Secondary antibodies included:
biotinylated anti-mouse IgG and biotinylated anti-rabbit IgG (1:1000, Vector Laboratories,
Burlingame, CA). Tissue was then washed 3 x 5 min with PBS followed by a 1 h of incubation
with Avidin Biotin Complex (ABC) (Vector Laboratories, Burlingame, CA). Sections were then
washed with PBS for 3 x 5 min and incubated with 3,3’-diaminobenzidine (DAB) (Sigma Aldrich,
St. Louis, MO) for 45-105 sec (dependent on antibody). Finally, sections were washed with PBS
3 x 5 min and mounted on to VistaVision microscope slides (VWR International, Radnor, PA)
with 0.3% gelatin (Fisher Scientific, Ottawa, ON). Mounted sections were left to dry until ready
for dehydration.
For primary antibody A11 (protocol was adapted from Kayed et. al., 2007123)
Sections were washed with PBS for 6 x 10 min washes to rid the cryoprotectant. An antigen
retrieval step was included in this protocol by washing the sections with 90% formic acid (SigmaAldrich, St. Louis, MO) for 4 min. Afterwards, sections were washed in double distilled water
(ddH2O) 3 x and then in PBS 2 x for 2 min per wash. This was followed by incubating the sections
in 3% hydrogen peroxide and 1% methanol for 30 min to block endogenous peroxidase activity
and to make the tissue more permeable for intracellular protein detection. Next, sections were
washed with Tris (0.1 M Tris base, 0.85% saline, pH 7.4-7.6), Tris A (Tris, 0.1% triton X-100
surfactant) and Tris B (Tris A, 2% bovine serum albumin) for 5, 15, and 30 min respectively.
Sections were incubated in primary antibody A11 (1:1000, Millipore, Billerica, MA), detects
oligomer-specific amyloid species, diluted in Tris B overnight on a shaker at RT (Table 2).
Sections were washed with Tris A and Tris B for 5 and 15 min respectively and then incubated in
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biotinylated anti-rabbit IgG (Vector Laboratories, Burlingame, CA) diluted in Tris B for 1 h at RT.
Sections were washed in Tris A for 2 x 5 min each and incubated in ABC kit diluted in Tris A for
1 h. Two x 5 min washes with Tris A and incubation in DAB diluted in Tris for 45-60 sec. Sections
from different surgical groups were stained at the same time. Finally, sections were washed in Tris
A for 2 x 5 min and mounted on to VistaVision microscope (VWR International, Radnor, PA)
slides with 0.3% gelatin (Fisher Scientific, Ottawa, ON). Mounted sections were left to dry until
ready for dehydration.
Sections from different surgical groups were stained at the same time, to ensure consistency
in immunohistochemical stains.
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Table 3. Summary of primary antibodies used in the experiments. Experimental uses indicate
which antibodies were used for western blot (WB) and immunohistochemistry (IHC).
Primary

Host Species

Target, Specific Binding

Experimental Uses

Mouse

Aβ protein, 17-24AA

WB, IHC

Aβ protein, oligomer-specific

WB, IHC

Mouse

Activated microglia, MHC

IHC

monoclonal

Class II

Rabbit

Microglia, ionized calcium-

polyclonal

binding adapter molecule

Mouse

Cholinergic neurons, choline

monoclonal

acetyltransferase

Antibody
Aβ4G8 (1:500)

monoclonal
A11 (1:1000)

Rabbit
polyclonal

Ox-6 (1:1000)

IBA-1 (1:1000)

ChAT (1:500)
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IHC

IHC

2.6

Dehydration and Cover Slip
Mounted sections on microscope slides were submerged in the following graded ethanol

washes: 50%, 70%, 95%, and 100% for 5 min each. Slides were then immersed in 50/50% solution
of ethanol and xylene for 5 min followed by 100% xylene for 10 min. Slides were then coverslipped (Fisher Scientific, Ottawa, ON) using depex (Electron Microscopy Sciences, Hatfield, PA)
mounting media.
2.7

Morris Water Maze
The maze consisted of a circular pool with diameter of 146 cm and height of 58 cm. Water

was filled until the platform was completely submerged and made opaque with non-toxic blue and
black paint. Visual cues were placed around the room to act as visual aids for rats to orient
themselves in the pool. Water was equilibrated to RT for at least 48 h before experiments began.
All trials were recorded with a video-tracking software (ANY-maze, Wood Dale, IL). The pool
was divided into four zones: northeast, northwest, southeast, and southwest. The platform was
placed in the southwest quadrant, which is referred to as the platform zone (Figure 3). Rats
received bilateral ICV injection of either AβO or PBS and allowed to recover for one week before
MWM began. All experiments were run in the morning to maintain consistency for circadian
rhythms.
Spatial Learning: Rats were subjected to four trials per day for four days between post-surgery
days 8 through 11. Trials were timed and automatically stopped either when the rat reached the
platform zone or after 90 sec had elapsed. If rats were unable to complete the task within 90 sec,
rats would be guided to the platform. After each trial, rats were allowed to rest on the platform for
30 sec. The placement of the rat in the pool varied for each trial and was randomly selected from
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one of four starting locations north, east, northeast, and southwest. Each location was used at least
once each day.
Probe trials: Probe trials occurred on post-surgery days 12 and 19 to test for the rat’s short- and
long-term spatial memory respectively124. In these trials, the platform was taken out of the pool
and the rats were allowed 30 sec to swim around. Only one trial occurred on each day.
Cued Trials: On post-surgery days 20 and 21, rats were tasked to find the platform with a visual
cue (yellow ball attached to a stand) placed on top of it. The purpose of this trial was to control for
the rats’ ability to recognize a visual cue and swimming ability124. Rats were subjected to four
trials per day.
Using the ANY-maze video-tracking software (ANY-maze, Wood Dale, IL) the following
measurements were calculated: latency to reach target zone, latency to reach platform zone and
mean swim speeds.
2.8

Open Field
To determine exploratory behavior and anxiety-like deficits, rats were subjected to open

field analysis (OF, Med Associates Inc., St. Albans, VT) on post-surgery day 21. Rats were
allowed to rest and acclimate to a new room where the behavioural task was performed, at a
minimum, four hours after their last cued trial in the MWM task. Each box was sprayed and wiped
down with ethanol before and after use. Boxes were divided into two zones: peripheral and central
(Figure 3). Laser sensors were lined across each of the four walls. Only one rat was put into each
locomotor box and was always placed at the front and center. Infrared beams were used to track
animal movement. Time measurements began automatically when the rat was placed in the box.
Rats were allowed to roam freely for 20 min. Analysis was performed using a video-tracking
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software, Activity Monitor (Med Associates Inc., St. Albans, VT). Ambulatory time, ambulatory
distance, and vertical counts were measured.
2.9

Brain Tissue Imaging and Analysis
Images were taken using a Nikon Eclipse Ni-U upright microscope built with a DS-Fi2

high-definition color camera and imaging software (Nikon Imaging Software- Elements), NISElements Colour Camera (Nikon Instruments, Melville, NY). Image analysis was completed
using ImageJ64 software (National Institute of Health, Bethesda, MD) by investigators that were
blinded to the surgical identity.
2.10

Statistical Analysis
GraphPad Prism 6.0 for Mac (GraphPad Software Inc., La Jolla, CA) was used for

statistical analysis. Data are expressed as group means ± the standard error of the mean (SEM).
Student’s t-tests or a two-way analysis of variance (ANOVA) followed a Tukey’s multiple
comparisons post-hoc test was performed where appropriate. * indicates statistical significance
between group means (p< 0.05).
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Figure 4. Chronological and structural representation of behavioural tasks including MWM
and open field analysis. (A) Amyloid beta oligomers (AβO) were incubated at 4°C for 24 hours
prior to surgeries. Rats were injected with either AβO (n=8) as treatment or PBS (n=8) as control.
MWM consisted of spatial learning (days 8-11), probe trial #1 for short term memory (day 12),
probe trial #2 for long term memory (day 19) and cued learning (days 20-21). Open field analysis
was performed in locomotor boxes on the last day before rats were euthanized 21 days postsurgery. Schematic diagrams representing (B) MWM and (C) open field analysis and the terms
reflecting the specific zones as addressed in the project. Location of the platform in MWM is
indicated by the green circle and was submerged under dark-colored opaque water.
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Part 3: Results
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3.1

Synthetic AβO were characterized using western blot
Synthetic AβO were produced in the lab for this study. The protocol used to prepare AβO

was based off an established protocol63. However, western blot was used to characterize the peptide
solution to ensure that AβO were indeed present. Two antibodies were used for this experiment
including Aβ4G8 and A11, which recognizes the 17-24 AA portion of the Aβ protein and Aβ
oligomers respectively. With these antibodies, the AβO that were detected were monomers,
dimers, trimers, tetramers and dodecamers (or Aβ*56) (Fig. 5). For comparison, we characterized
the peptide solution prior to and following the oligomerization step of the protocol (before and
after the 24 h incubation at 4°C). Similar immunoblot band patterns were observed both prior and
following the oligomerization process. Additionally, we also examined the effect of adding
dithiothreitol (DTT), a reducing agent, in the loading dye. With DTT, dodecamers were observed
with the A11 antibody. Without DTT, dodecamers were not observed with A11 antibody but a
series of vertical bands above the dodecamer was detected. These bands could potentially be higher
molecular weight (HMW) oligomers. These results were consistently found after repeating the
experiment multiple times.
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Figure 5
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Figure 5. Immunoblotting of synthetically prepared amyloid beta oligomers. Antibodies
against Aβ- A11 (top, oligomer-specific) and 4G8 (bottom, 17-24AA) were used to detect amyloid
beta oligomers. Samples were either incubated for 0 h (pre-oligomerization) or 24 h (post
oligomerization) at 4°C and with or without dithiothreitol (DTT) when loading the sample in SDSPAGE. Gels were run in tris-tricine buffer. 4G8 blots indicated presence of monomers, dimers,
trimers, and tetramers in all lanes. Dodecamers (or Aβ*56) were detected in A11 blots in the
absence of DTT. When loading samples contained DTT, no dodecamers but potentially higher
molecular weight (HMW) oligomers were detected.
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3.2

AβO deposition was detected in sections adjacent to ventricular injection sites
To determine AβO deposition after injecting either AβO or PBS into the ventricles,

immunohistochemical stains were done on brain sections with the Aβ4G8 antibody. Positive
staining in rats injected with AβO was detected within the ventricular walls and along the needle
track within the corpus callosum in sections adjacent to the injection site (Fig. 6). Optical
densitometry (OD) measurements were significantly higher in the corpus callosum above the
ventricles between 1-day and 3-day AβO rat groups with 21-day AβO rat group. No positive
labeling was detected in any of the PBS groups at any time point.
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Figure 6. Detection of Aβ deposition following ICV injections of AβO. (A) Rat brain atlas photo
depicting area where photomicrographs were taken, red box indicates area of interest. (B)
Representative photomicrographs of immuno-histochemical labeling with the Aβ4G8 antibody of
sections adjacent to bilateral ventricular injection sites 1, 3, 7 and 21-days post-surgery. Black box
indicates area magnified in bottom row. Black arrows indicate positive Aβ4G8 labeling. Positive
Aβ4G8 labeling was not detected in any PBS groups. (C) Quantification of Aβ4G8 labeling.
Optical densitometry measurements show a significant decrease was observed in rat groups
injected with AβO in 1 and 3-days with 21-days post surgery. Statistical analysis consisted of twoway ANOVA and Tukey’s multiple comparison’s test. Scale bars indicate either 100 or 200 µm.
All groups had an n=5. Data are expressed as means ± SEM. * indicates statistical significance, p
< 0.05.
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3.3

AβO deposition was detected in walls of ventricles distal from the injection site
In addition to finding Aβ deposition in sections adjacent to the injection site, positive

Aβ4G8 staining was also observed within the walls of the lateral and third ventricles in sections
distal to the injection site (Fig. 7). Sections that were positively labeled were approximately 1.8 ±
0.1 mm posterior to the injection site. Although positive Aβ4G8 staining was never consistently
found in one area, positive staining was observed within the ventricular walls of all AβO groups.
The number of rats that had Aβ4G8 positive staining in the lateral ventricles or third ventricles are
summarized in a table (Fig. 7). In our semi-quantitative analysis, Aβ deposition was determined if
positive staining was observed within the walls of either the lateral ventricles or in the third
ventricle. The analysis showed that Aβ deposition within the ventricle walls was more apparent 1
day post-surgery compared to 3, and 7 days post-surgery. By 21-days post-surgery, Aβ deposition
was only detected in two animals and only minimal positive labeling was observed. One 21-day
post-surgery rat had positive staining within the lateral ventricles only and the other had positive
staining within the third ventricle only. No positive Aβ4G8 labelling was observed within the walls
of ventricles of any PBS injected rat group.
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Figure 7. Detection of Aβ deposition around ventricles following ICV injection of AβO with
Aβ4G8. (A) Rat brain atlas photo depicting areas where photomicrograph images were taken as
indicated with black boxes. Representative photomicrographs of immuno-histochemical stains
with Aβ4G8 antibody of lateral and third ventricles at (B) 1, (C) 3, (D) 7, and (E) 21-days post
surgery. Sections were approximately 2.6 ± 0.1 mm posterior to bregma. Positive labeling was
detected within ventricular walls. No positive labelling was observed in any PBS rats. (F) Semiquantitative analysis summarized in a table of rats that had positive Aβ4G8 labeling within
ventricular walls. Scale bars indicate 200µm.
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3.4

No AβO deposition was detected within the hippocampus
One of the first regions for Aβ deposition in AD brains occur in the hippocampus 44. To

determine whether Aβ was deposited within the hippocampus following ICV AβO injection,
sections were immunohistochemically stained with Aβ4G8 and A11 antibodies. Qualitative
observations for positive labeling were not observed in the hippocampus in any surgical group.
OD measurements for labeling intensity within the hippocampus also showed no significant
differences between AβO and PBS groups with either Aβ4G8 or A11 antibodies (Fig. 8).
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Figure 8. Detection of Aβ deposition in hippocampus following ICV injection of AβO. (A)
Rat brain atlas photo depicting area where photomicrograph images were taken as indicated with
the black box. Representative photomicrographs of immuno-histochemical stains with (B) Aβ4G8
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and (C) A11 antibodies of the hippocampus at 1, 3, 7, and 21-days post-surgery. Sections were
approximately 2.6 ± 0.1 mm posterior to bregma. No observable differences in positive labeling
were detected with either antibody in the hippocampus. (D) Quantification of Aβ4G8 labeling. (E)
Quantification of A11 labeling. No significant differences were observed in optical densitometry
measurements with either antibody. Statistical analysis consisted of two-way ANOVA. Scale bars
indicate 1 mm. All groups had an n=5. Data are expressed as means ± SEM.
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3.5

No microglial responses were observed within the hippocampus
Although AβO deposition was not detected within the hippocampus, a microglia response

within the hippocampus may still have occurred. Increased microglial response is one of the
earliest pathological consequences in AD pathogenesis and the hippocampus is one of the first
regions to be affected125. Microglial response was characterized by labeling for activated microglia
(Ox-6) and all microglia types (IBA-1) (Fig. 9). No qualitative differences were observed between
rats injected with AβO or PBS in 1, 3, 7, and 21-days post-surgery. No significant differences in
microglial cell counts with Ox-6 labeling were observed within the hippocampus. OD
measurements of IBA-1 labeling were also measured and no significant differences were observed
either.
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Figure 9. Microglial response in hippocampus following ICV injection of AβO. (A) Rat brain
atlas photo depicting area where photomicrograph images were taken as indicated with the black
box. Representative photomicrograph of immuno-histochemical stains with (B) Ox-6 and (C) IBA1 antibodies of the hippocampus at 1, 3, 7, and 21-days post-surgery. Sections were approximately
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2.6 ± 0.1 mm posterior to bregma. No observable differences in microglial response were detected
with either antibody in the hippocampus. Quantification of microglial staining cell counts and
intensity response with (D) Ox-6 and (E) IBA-1 labeling respectively. No significant differences
were observed in either microglial cell counts or optical densitometry measurements. Statistical
analysis consisted of two-way ANOVA. Scale bars indicate 1 mm. All groups had an n=5. Data
are expressed as means ± SEM.
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3.6

No differences in microglial responses observed within the basal forebrain and

corpus callosum
Another brain region often associated with increased microglial responses in AD patients
is the basal forebrain18. Microglia responses in basal forebrain were assessed with Ox-6 and IBA1 (Fig. 10). No qualitative differences were observed between rats injected with AβO or PBS at 1,
3, 7, and 21-days post-surgery. A few activated microglia, stained with Ox-6, can be found in the
basal forebrain of some rats but occurred equally in both AβO and PBS groups. Microglial cell
counts were measured and no significant differences were observed. With IBA-1 antibody,
microglial cells were stained throughout the region and were consistently found in all groups,
however, no differences with respect to cell morphology or number was observed. In addition, OD
measurements of IBA-1 labeling intensity also showed no significant differences.
Within the corpus callosum, superior to the basal forebrain, activated microglia were often
observed with Ox-6 (Fig. 10). However, the Ox-6 staining of activated microglia was found
equally in both AβO and PBS groups. Similarly, OD measurements of IBA-1 also showed no
significant differences between AβO and PBS injected rats.
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21

Figure 10. Microglial response in basal forebrain and corpus callosum following ICV
injection of AβO. (A) Rat brain atlas photo depicting area where photomicrograph images were
taken. Representative photomicrograph of immuno-histochemical stains with (B) Ox-6 and (C)
IBA-1 antibodies of the basal forebrain and corpus callosum at 1, 3, 7, and 21-days post-surgery.
Sections were approximately 0.7 ± 0.1 mm anterior to bregma. No observable differences in
microglial response were detected with either antibody. Quantification of microglial response with
Ox-6 antibody was measured by microglial cell counts in basal forebrain (D) and corpus callosum
(E). Quantification with IBA-1 antibody was measured by staining intensity within the basal
forebrain (F) and corpus callosum (G). No significant differences were observed in any of the
measurements. Statistical analysis consisted of two-way ANOVA and Tukey’s multiple
comparison’s test. Scale bars indicate 1 mm. All groups had an n=5. Data are expressed as means
± SEM.
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3.7

Microglial activation in white matter regions: internal capsule and fimbriae of

hippocampus
White matter damage and degeneration have been previously characterized with AD116.
Qualitative analysis of the tissue sections immunostained with Ox-6 antibody found activated
microglia being labelled within white matter regions of the brain (Fig. 11). Therefore, quantitative
analysis by microglial cell counts was done in areas of interest based on qualitative observations,
which included internal capsule and fimbriae of the hippocampus. Data indicated no significant
differences in microglia cell counts between AβO and PBS groups across all time points within
the internal capsule and fimbriae of hippocampus.
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Figure 11. Microglial response in internal capsule (IC) and fimbriae of hippocampus (FoH)
following ICV injection of AβO. (A) Rat brain atlas photo depicting area where photomicrograph
images were taken as indicated with the red box, IC, and black box, FoH. Representative
photomicrograph of immuno-histochemical stains with Ox-6 antibody in (B) IC and (C) FoH at 1,
3, 7, and 21-days post-surgery. Sections were approximately 2.6 ± 0.1 mm posterior to bregma.
Cell counts of microglia in (D) IC and (E) FoH. No significant differences were observed in optical
densitometry measurements. Statistical analysis consisted of two-way ANOVA. Scale bars
indicate 1 mm and 200 µm. All groups had an n=5. Data are expressed as means ± SEM.
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3.8

Cholinergic neuron depletion in basal forebrain
In addition to inflammation, cholinergic neuron loss is one of the earliest pathological

changes in AD patients. This neuron loss occurs within the basal forebrain, specifically the medial
septal nucleus (MS) and vertical and horizontal diagonal bands of Broca (vdbb and hdbb)127.
Therefore, immunohistochemistry for choline acetyltransferase (ChAT) was done to label
cholinergic neurons within the basal forebrain following exposure to ABO (Fig. 12). No significant
differences were found in MS, vdbb, and hdbb areas between AβO and PBS groups at 1, 3, 7, and
21-day post-surgery when two-way ANOVA was performed on the cholinergic neuron counts.
However, a trend at 21-day post-surgery suggests that rats injected with AβO had less cholinergic
neuron counts compared to PBS control. This may suggest that AβO injected into the ventricles
can affect cholinergic neuron viability at 21-days post-surgery compared to PBS group.
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Figure 12. Cholinergic neuron depletion in basal forebrain following ICV injection of AβO.
(A) Rat brain atlas photo depicting area where photomicrograph images were taken. (B)
Representative photomicrograph of immuno-histochemical stains with ChAT antibody of the
medial septal nucleus, vertical and horizontal diagonal bands of Broca at 1, 3, 7, and 21-days postsurgery. Sections were approximately 0.8 ± 0.1 mm anterior to the bregma. (C) Cell counts of
cholinergic neurons were quantified. No significant differences were observed although a trend
exist at 21-days post-surgery where there are less cholinergic neurons in AβO group compared to
PBS. Statistical analysis consisted of two-way ANOVA. Scale bars indicate 1 mm. All groups had
an n=5. Data are expressed as means ± SEM.
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3.9

Cognitive deficits in spatial memory determined by the Morris water maze
To test for spatial learning and memory of rats after ICV injection of either AβO or PBS,

Morris water maze (MWM) was performed on 21-day rat groups. Through post-surgery days 8 to
11, rats underwent four spatial learning trials per day to learn the location of the hidden platform
in the pool. Both AβO and PBS rats were successful in learning the task after four days of spatial
learning as the latency to reach platform decreased steadily on each day (Fig. 13).
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Figure 13. Mean latency to reach platform on spatial learning days in Morris Water Maze
task. Rats injected with either AβO (n=8) or PBS (n=7). On post-surgery days 8-11, rats were
subjected to spatial learning with four trials per day. Both AβO and PBS groups were successful
in learning the task. Statistical analyses consisted of two-way ANOVA. Data are expressed in
means ± SEM.
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To test for short- and long-term spatial memory, rats underwent two probe trials on days 12 and
19. No significant differences were observed in the latency to reach target zone between AβO and
PBS groups. Significant differences, however, were observed in latency to reach platform zone
between AβO and PBS groups on day 12 but not day 19 (Fig. 14). This suggests a subtle and
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Figure 14. Comparing latency to reach target and platform zone on probe trial days. Mean
latency to reach (A) target zone and (B) platform in Morris Water Maze task for rats injected with
either AβO (n=8) or PBS (n=7) at 12 or 19-days post surgery. Rats were subjected to one 30 second
probe trial to test for short-term memory (day 12) and long-term memory (day 19). Rats treated
with AβO had a significantly greater latency to reach platform in short-term probe trial (Day 12)
when compared to control group. No significant differences were observed elsewhere. Statistical
analyses consist of two-way ANOVA followed by Tukey’s multiple comparisons test. Data are
expressed as means ± SEM. * indicates statistical significance, p < 0.05.
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The MWM relies on the rat’s ability to visualize cues around the pool to learn and recall the
location of the hidden platform. To ensure that the rats did not differ in their ability to visualize
the cues, cued learning trials were included for the MWM task on days 20 and 21 post-surgery.
Both AβO and PBS injected rats were able to find the platform and showed no significant
differences in the mean swim speeds between AβO and PBS groups on cued learning days 20 and
21 (Fig. 15). Mean swim speeds help determine the rats’ ability to swim, which may also affect
the latency to reach platform zone. During spatial learning days 8-11, the mean swim speed of rats
injected with AβO were significantly slower on day 8 than PBS rat group (Fig. 16). This may
suggest that AβO rats are not as active in the pool, however, this significant difference disappears
in subsequent days of the MWM task. Additionally, swim speeds of the PBS group at day 11 was
significantly slower than at day 8 and no differences were observed between the groups at day 11
(Fig. 16). More importantly, no significant differences in swim speeds were observed during probe
trials on day 12 and 19, therefore probe trials are not biased due to differences in swim speeds.
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Figure 15. Mean swim speed of rats during cued learning in Morris Water Maze task. Rats
were injected with either AβO (n=8) or PBS (n=7). Rats were subjected to cued learning on postsurgery days 20 and 21. No significant differences were observed between AβO and PBS control.
Statistical analyses consisted of two-way ANOVA. Data are expressed as means ± SEM. *
indicates statistical significance, p < 0.05.
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Figure 16
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Figure 16. Mean swim speed of rats during spatial learning and probe trials in Morris Water
Maze task. Rats were injected with either AβO (n=8) or PBS (n=7). Rats were subjected to spatial
learning (days 8-11), a short-term (day 12) and long-term (day 19) probe trial. Significant
differences in average speed were observed between rats treated with AβO and PBS control group
on day 8 of spatial learning and the first and last day of spatial learning of the PBS group. Statistical
analyses consists of two-way ANOVA followed by Tukey’s multiple comparisons test. Data are
expressed as means ± SEM. * indicates statistical significance, p < 0.05.
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3.10

Behavioural differences in exploratory and anxiety–like behavior as determined by

open field analysis
Rats were subjected to the open field test 21 days post-surgery. This test characterizes
exploratory and anxiety-like behavior128. AβO-treated rats showed significantly less total
ambulatory distance and total ambulatory time in the first 5 min of the analysis compared to
controls suggesting reduced exploratory behaviour. (Fig. 17). To understand the differences more
specifically, total ambulatory time and distance was separated into regions of the peripheral and
the central zones. No significant differences were observed in ambulatory time and distance in the
peripheral zone, but significant differences in ambulatory distance and time were observed in the
central zones. Rats injected with AβO had significantly less ambulatory distance and time in the
central zone compared to PBS injected rats. This indicates that AβO rats showed signs of anxietylike behaviour. Although a similar trend was observed in the peripheral zone, a significant
difference was not established. No significant differences were observed in total vertical counts of
either AβO or PBS groups suggesting normal locomotor activity (Fig. 18).
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Figure 17. Comparing ambulatory distance and time of rats in open field analysis. (A) Total ambulatory
distance and (B) time. (C) Ambulatory distance and (D) time in central zone. (E) Ambulatory distance and (F)
time in peripheral zone. Rats were injected with either AβO (n=8) or PBS (n=7). Rats were subjected to open
field analysis on Day 21. Significantly lower total ambulatory distance and time and ambulatory distance and
time in central zone were observed in rats treated with AβO compared to PBS control during the first five minute
time block. This suggests AβO treated rats have increased anxiety-like behavior. No significant differences were
observed in peripheral zone. Statistical analyses include two-way ANOVA followed by Tukey’s multiple
comparisons test. Data are expressed as means ± SEM. * indicates statistical significance, p < 0.05.
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Figure 18. Mean of the total vertical counts made by each rat during open field analysis. Rats
were injected with either amyloid beta oligomers (AβO, n=8) or phosphate buffered saline (PBS,
n=7). No significant differences in total vertical counts, a measure for exploratory behavior, were
observed. Statistical analyses include an unpaired t-test. Data are expressed as means ± SEM.
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3.11

No differences in body weight measurements
Body weights were also measured each week during the behavioural assessment of the rats.

No significant differences were observed between AβO and PBS groups at each time point (Fig.
19). The observed decrease in weight at day 14 in both AβO and PBS rats may correspond with
increased activity during behavioural assessments.
recovered by post-surgery day 21.
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Body weights of both groups however,

Temporal Changes in Rat Body Weight Differential
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Figure 19. Changes in body weight of rats sacrificed 21-days post surgery. Changes in body
were measured relative to their weight at Day 0. Rats were weighed at 7, 14 and 21-days postsurgery and injected with either AβO or PBS. No significant differences were observed. Statistical
analyses include two-way ANOVA. Data are expressed in means ± SEM.
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Part 4: Discussion
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4.0

Discussion
AβO are considered key initiators in the pathogenesis of AD43,105. Here, we established a

temporal profile for AβO deposition within the walls of ventricles after ICV injections. We
examined the microglial response within the hippocampus, basal forebrain and white matter
regions such as corpus callosum, internal capsule and fimbriae of the hippocampus. In addition,
we observed a trend in cholinergic neuron depletion in the basal forebrain after exposure to AβO
21-days post-surgery. We also demonstrated that rats exposed to AβO displayed a subtle and
transient deficit in spatial learning and memory with MWM; and anxiety-like behaviour with the
OF test.

4.1

Characterization of synthetic AβO preparation with western blot
The method used in this study to produce synthetic AβO was based on an established

protocol that was first published by Lambert et. al., 199863. The purpose of this experiment was to
ensure that our preparation contained the oligomeric form of Aβ. Our data showed the presence
of dimers, trimers, tetramers, and dodecamers. Studies using similar preparations of synthetic AβO
and characterization using western blot, with primary antibodies 4G8 and A11, found comparable
results129,130. Another study using similar synthetic AβO preparations also characterized these
structures using western blot and with the Aβ primary antibody 6E10 identified a much wider
range of AβO that consisted of dimers to 24mers71. This may have resulted from the different
epitopes recognized by the antibodies: 6E10 binds to 1-16 amino acids (AA) whereas 4G8 binds
to 17-24AA of the Aβ peptide sequence. Interestingly, our western blot analysis detected AβO
prior to the ‘so called’ oligomerization step where samples are incubated for 24 h at 4°C. This,
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however, could be explained by the SDS-stable properties of AβO as Aβ monomers (preincubation) could have oligomerized in the presence of SDS during western blot analysis54,69.
Many techniques have been used to characterize AβO such as atomic force microscopy, western
blot, electron microscopy, and size exclusion chromatography63,71,116. These techniques, however,
do not identify all the same structures in the AβO preparation, suggesting that different
environments and experimental protocols can affect the characterization of the peptide solution.
This can also be seen in our study when we varied the addition of dithiothreitol (DTT) in our
loading dye. Without DTT, our results detected dodecamers with the A11 antibody, which was not
observed when DTT was present. Instead, with DTT in the loading dye a series of vertical bands
at approximately 95 kDa was observed. These vertical bands could potentially indicate higher
molecular weight (HMW) AβO as observed in a study by Chromy et. al., 200371. Ultimately, this
experiment helped ensure that the peptide solution contained AβO and that our preparation is
comparable to others used in the field.

4.2

Aβ deposition in the brain after ICV injections
In this study, we found positive Aβ immuno-labeling within the walls of ventricles but not

in the brain parenchyma. This could indicate that AβO were not crossing from the ventricles into
the parenchyma, or alternatively, we were unable to detect the Aβ deposition due to the insufficient
accumulation of AβO in specific parenchymal regions. In this study, we performed a one time
bilateral ICV injection of approximately 23 µg of AβO into the lateral ventricles. For comparison,
a similar study used immuno-labeling to detect AβO deposition and found positive labeling in
distinct brain regions such as, entorhinal cortex, hippocampus, amygdala, and striatum. In this
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study they performed ICV injections of 1 µg of AβO 3 times a week for 5 weeks into Wistar rats,
which amounted to a total of 15 µg of AβO122. This suggests that chronic injections of AβO in
smaller amounts may allow more peptide to cross into the parenchyma and accumulate in specific
regions than a single injection of a larger quantity. With more AβO in the parenchyma and in
specific brain regions, the immuno-labeling may be easier to detect under the microscope.
Our study also found that Aβ immuno-labeling within ventricular walls was less visible at
21 days post injection. This may suggest that AβO injected into the lateral ventricles accumulate
within the walls of ventricles before gradually diffusing into the brain parenchyma in the
subsequent days following surgery. Previously, studies in human AD patients and AD mice models
have correlated decreases in AβO levels in cerebrospinal fluid (CSF) with increases in Aβ
deposition in the brain66,75,131,132. These studies suggest that an unknown mechanism must exist
that allow AβO to cross into the brain parenchyma as the disease worsens. This idea that AβO in
the CSF can cross into the parenchyma was also demonstrated by Forny-Germano et. al., 2014122.
In their study, rats received chronic ICV injections of AβO and were sacrificed 40 days after their
first exposure to AβO. In their analysis, AβO were found to accumulate in specific regions
throughout the rat brain. It is also important to note that we were unable to identify a specific area
where positive immuno-labeling occurred consistently within the walls of the ventricles. Thus, we
suspect that AβO injected into the ventricles randomly accumulated in different areas within the
ventricular walls. Combining these findings, we propose that AβO in the CSF would accumulate
in walls of ventricles before crossing into the brain parenchyma. Once within the brain
parenchyma, AβO diffuses across the brain and accumulates in regions that are more vulnerable
to AβO accumulation. Interestingly, the areas identified by Forny-Germano et. al., 2014122 were
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consistent with the areas described by Thal et. al., 200244 where the study described the spatiotemporal progression of Aβ deposition in the human AD brain. Overall, our findings provide
insight into a potential pathway for AβO in the CSF to cross into the brain parenchyma, by first
accumulating in the walls of ventricles and then diffusing in to specific brain regions.

4.3

Microglial response following AβO exposure in the rat brain
Microglial activation is an early pathological consequence to AβO deposition, and has been

observed in the basal forebrain, hippocampus, and white matter regions105,125,126,133–135. Previously
in our lab, we found that ICV injections of Aβ25-35 induced microglial activation within the
hippocampus and basal forebrain94,102. Given that AβO are potent neurotoxic proteins that can
induce microglial activation in vitro105,121,136, we hypothesized that injection of AβO would result
in increased microglial activation in the brain. Contrary to our hypothesis, we did not observe any
significant differences in microglial response within the hippocampus, basal forebrain, corpus
callosum, internal capsule, and fimbriae of the hippocampus. These results suggest that our model
of bilateral ICV injection of synthetic AβO does not activate microglial response in the brain based
on the techniques used in this study. Other studies however, have found that synthetic AβO can
induce microglial response in vivo in rodent models121,122, but the studies differed in area of
injection (directly in the hippocampus) or the way it was administered (multiple injections over a
span of several weeks). Additionally, inflammatory responses in AD consist of many other factors
such as astrocytes and different cytokines and chemokines such as IL-1, IL-6, TNF-α, etc.15.
Although our study did not demonstrate an increased inflammatory response via activated
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microglia after AβO exposure, that does not eliminate other inflammatory responses that could
have occurred and should be examined in future studies.

4.4

Cholinergic depletion in basal forebrain after AβO exposure
Previously in our lab, we demonstrated that ICV injection of Aβ25-35 resulted in a

cholinergic neuron depletion in the basal forebrain94. Other studies have also demonstrated that
AβO with can impair cholinergic activity in vitro and in human AD patients137,138. For these
reasons, we were interested to see if ICV injection of AβO would result in a loss of cholinergic
neurons. Although we were unable to find any significant changes in cholinergic neuron numbers
within the basal forebrain region (medial septum, vertical and horizontal diagonal bands of Broca),
we found that a trend at 21-days post surgery that AβO injected rats had less cholinergic neurons
than the control group. This is interesting as cholinergic neurons in these areas innervate neurons
in the hippocampus139, which may help explain the subtle and transient cognitive deficits in spatial
learning and memory with MWM. This idea is supported by Ozdemir et. al., 2013140, where rats
were injected with a mixture of synthetic AβO derived from Aβ1-40 and Aβ1-42 directly into the
medial septum of the basal forebrain. These rats displayed mild cognitive deficits in spatial
learning and memory with the MWM task. Mainly, decreased cholinergic activity in the medial
septum has been implicated in human patients to correlate with increased anxiety141, which also
supports our findings of anxiety-like behaviour in rats exposed to AβO. Ultimately, no significant
differences were observed and future studies could be done to examine the relationship between
AβO and cholinergic neuron depletion.
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4.5

Cognitive and behavioural deficits in MWM and OF
Our study did not demonstrate significant pathological differences in microglial response

or cholinergic neuron depletion, but did observe significant differences in our behavioural tests
with the MWM and OF test.
MWM is a common behavioural task used to test AD models for cognitive deficits in
spatial learning and memory81,86,142. In our MWM task, we found that during the probe trial on
post-surgery day 12, ICV injected AβO rats had a higher latency to reach the platform zone, but
no significant differences were observed in the latency to reach the target zone. This suggests that
rats injected with AβO could remember the general area of the platform but cannot locate the
platform as precisely compared to the control group. Further, no significant difference was
observed during the probe trial on post-surgery day 19. It is important to note that this was mainly
due to the control rats performing worse and spending more time to reach the platform zone on
post-surgery day 19 compared to day 12. A previous study in our lab by Nell et. al., 201494 also
demonstrated deficits in spatial learning and memory with MWM after ICV injection of Aβ25-35.
Overall, we conclude that ICV injected AβO rats demonstrated a subtle and transient deficit in
spatial learning and memory.
In our OF analysis, we found that AβO rats spent significantly less time in the central zone
compared to control in the first five minutes of the task. This may suggest that ICV injected AβO
rats showed anxiety-like behaviour compared to controls128. This was an interesting finding as
anxiety is a common early clinical symptom observed in AD patients7. Previously other studies
using the Tg6590 AD rat model and characterized anxiety-like behaviour with OF, interestingly
this study also found deficits in spatial learning and memory with MWM and found elevated levels
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of AβO in the hippocampus and cortex. Overall, our study demonstrated that injecting AβO into
the rat brain resulted in deficits in spatial learning and memory and anxiety-like behaviours.

4.6

Study Limitations
The first limitation of our study is the inability to correlate a particular species of AβO for

causing the behavioural and cognitive deficits observed in our study. With our western blot
analysis, we identified monomers, dimers, trimers, tetramers, and dodecamers within our AβO
preparation. Since the field has previously identified dimers, trimers, and dodecamers as potent
neurotoxic proteins perhaps each species was a factor in the behavioural and cognitive deficit.
A second limitation is our inability to identify whether the synthetic AβO preparation
remained the same structurally after being injected into the brain. AβO have the potential to change
into other forms of Aβ peptides such as Aβ protofibril and fibrils after being exposed to the
physiological environment143. However, our synthetic AβO preparation is one of the most
established protocols in the field. It has been characterized by a variety of methods including,
atomic force microscopy, size exclusion chromatography, electron microscopy, and western blot.
Thus we can still be confident that AβO were injected into the brain.
Another potential limitation is that the synthetic AβO preparation is not ‘naturally’-derived
(derived from either human AD brains, animal AD-brain models or cell-derived). Naturallyderived AβO are also considered more potent67,144, however, synthetic AβO are more accessible
since they can be produced within the laboratory and in the absence of AD models or human AD
brains.
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Another potential limitation is the genetic variability of outbred Wistar rats77. AD is a
complex disease and many genetic factors that are identified in humans can contribute to increased
susceptibility34. Therefore, using outbred Wistar rats will greatly enhance genetic variability which
may result in greater variability with pathological responses.

4.7

Future Studies
In our study, we demonstrated that exposing a non-transgenic rat brain with synthetic AβO

resulted in subtle cognitive and behavioural deficits in the absence of microglial activation or
cholinergic depletion. A next logical step would be to change certain parameters of the study to
see if we can induce greater pathological and behavioural consequences, such as the method of
AβO administration and longer time periods for AβO exposures in the brain. Instead of a single
injection, we could chronically inject AβO into the rat brain over a period of several weeks.
Perhaps by performing chronic injections, we may better mimic the gradual accumulation of AβO
in the brain seen in AD patients. This in turn may allow AβO to accumulate more in the
parenchyma and induce greater pathological changes. As a result, we can also examine behavioural
consequences with MWM and OF. In our study, we studied microglial response and cholinergic
neurons depletion. We could however, examine other pathological aspects using this model such
as amyloid plaque deposition, neurofibrillary tau formation, synapse loss, and other inflammatory
markers i.e. astrocyte response 15,34.
Another potential study would be to examine the effects of synthetic AβO in a transgenic
rat AD model. Currently available in our lab is the APP21 transgenic rat model. Interestingly, this
rat model, although overexpresses mutated human-APP and produces high levels of Aβ1-40 and

78

Aβ1-42, do not develop plaques up to 30-months of age83,145. Therefore, it would be interesting to
observe whether injecting synthetic AβO could induce greater pathological and behavioural
outcomes compared to APP21 rats without synthetic AβO injected into their brains.
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Part 5: Summary and Conclusions
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5.1

Summary of Findings
•

AβO were detected along the injection track in sections adjacent to the injection site at 1,
3, 7 and 21-days post-surgery.

•

AβO deposition were detected within the walls of the ventricles throughout the brain, but
never consistently found in a specific area at 1, 3, 7 and 21-days post-surgery.

•

AβO deposition was not detected in the brain parenchyma of sections remote to the
injection site.

•

No significant differences in inflammatory (activated microglia) responses were observed
between AβO and control PBS groups at 1, 3, 7, and 21-days post-surgery within the
hippocampus, basal forebrain, and white matter regions: corpus callosum, internal capsule,
and fimbriae of hippocampus.

•

Significant differences were not observed with cholinergic neurons in the basal forebrain.
A trend, however, occurs at 21-days post surgery that may suggest AβO depletion of
cholinergic neurons.

•

Subtle and transient cognitive deficits in spatial learning and memory were observed with
the Morris water maze in AβO injected rats compared to control.

•

Anxiety-like behavior was observed in rats injected with AβO compared to controls in the
open field test. No significant differences were found with exploratory behavior with
vertical counts.
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5.2

Conclusion
This study demonstrated that synthetic AβO injected into a non-transgenic rat does not

result in significant changes in microglial response in hippocampus, basal forebrain, corpus
callosum, internal capsule, and fimbriae of hippocampus. Although a trend occurred at 21-days
post surgery, no significant changes in cholinergic neuron numbers were observed in the medial
septum and vertical and horizontal bands of Broca of the basal forebrain. However, our study does
show that synthetic AβO injection result in a subtle and transient deficit in spatial learning and
memory with MWM as well as anxiety-like behaviour with OF.
Our findings also demonstrated positive Aβ labeling within the walls of ventricles early
after AβO injection which decreased over time. This study proposes a possible mechanism for
AβO located within the CSF to cross into the brain parenchyma by first accumulating within the
walls of ventricles before diffusing across and accumulating in specific brain regions. With
growing evidence for AβO as a potential mediator in the pathogenesis of AD, it is crucial for the
field to understand the effects of AβO in vivo. These results can help further our understanding of
AD and also provide insight for novel therapeutic treatments.
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Figure 20. No primary antibody control for immunohistochemical stains. Photo-micrographs
depicting (A) hippocampus and fimbriae of hippocampus, (B) basal forebrain, (C) lateral ventricle,
and (D) internal capsule.
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